Medannex Advances First ANAX1 Antagonist With Modular Cancer Trial Approach
Emerging Company Profile: The Scottish biotech is the only firm targeting the ANAX1 protein with plans to initiate a modular Phase I trial that could look at multiple tumor types before expanding to the autoimmune space.
You may also be interested in...
Real-world cases of retinal vasculitis linked with Syfovre for geographic atrophy in age-related macular degeneration may have resulted from a material used in a specific filter needle, the US firm revealed, as analysts remained optimistic on the product.
Geron’s highly anticipated telomerase inhibitor has been given a user fee date by the US Food and Drug Administration next year and will also be subject to an advisory committee meeting, despite largely positive analyst sentiment on clinical results to date.